Abbreviations: MDS, myelodysplastic syndromes; Ins, insertion; ITD, internal tandem duplications; nt, not tested; wt, wild type. Expression of a marker was defined as at least 20% positive cells compared with the corresponding negative control.
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Survival is presented as the survival from start of treatment. 
Partially Characterized Molecules (n=3)
Partially Characterized Molecules ↑ Glucuronide of C8H16O2 (1) ↓ Glucuronide of C10H18O2 (7) ↓ Glucuronide of C14H22O4 (2) Figure S1 . Timeline of treatment schedule for patients included in two clinical studies. In the first study shown at the top (Ryningen et al.), patients were give ATRA alone for two days before theophylline and valproic acid were given on day 3. Samples were collected pretherapy (day 1) and after 2-days of ATRA treatment. In the second study shown at the bottom (Fredly et al.) , patients received valproic acid alone for 7 days before ATRA and then subsequently cytarabine were given. Samples were collected pretherapy (day 1) and after 7 days of valproic acid therapy. Figure S4 . Pathway enrichment analysis based on metabolite levels that differed in patients pretherapy compared to during ATRA treatment for responders and non-responders to antileukemic treatment. The analysis was based on significantly altered metabolites (p<0.05), and only signaling pathways with an enrichment value greater than two and at least two metabolites within each pathway are shown in the figure. The most significant pathway is shown in red and less significant pathways in light yellow. 
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